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Objective: To assess the frequency, clinical presentation and outcome associated with
saddle pulmonary embolism (PE) diagnosed by computed tomographic angiography (CTA).
Patients: Retrospective review of 546 consecutive patients diagnosed to have acute PE by
CTA from 1 September 2002 to 31 December 2003.
Results: Fourteen of 546 patients (2.6%) had saddle PE; 10 were men (71%). None of these
patients had pre-existing cardiopulmonary disease. Most common presenting symptoms
included dyspnea (72%) and syncope (43%). Hypotension was documented in 2 patients
(14%). The most common risk factor for PE was obesity (64%). CTA revealed saddle PE and
additional filling defects in the main pulmonary arteries in all patients. Echocardiography
was performed within 48 h of the PE diagnosis in 10 patients and revealed right ventricular
dysfunction in 8 (80%). All patients were initially managed in the hospital, median length of
stay of 4 days (range, 1–45 days). Standard anticoagulant therapy with heparin and
warfarin was administered to all patients. Five patients (36%) received additional therapy;
thrombolytic therapy was administered to 1 patient (7%) and 4 patients (29%) received an
inferior vena cava filter. None of the patients died during their hospitalization. Four
patients (29%) died following their hospitalization after intervals of 1, 5, 6, and 12 months,
respectively. Causes of death were known in 3 patients, all of whom died from progressive
malignancy.Elsevier Ltd. All rights reserved.
graphic angiography; PE, pulmonary embolism; RV, right ventricle
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J.H. Ryu et al.1538Conclusion: Saddle PE in patients without pre-existing cardiopulmonary disease is
associated with a relatively low in-hospital mortality rate and may not necessitate
aggressive medical management.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Pulmonary embolism (PE) remains a common cause of
mortality and morbidity.1–4 In particular, massive PE (defined
by a systolic blood pressureo90mmHg) has been associated
with a 90-day mortality rate of 52.4% despite treatment.5
Treatment options beyond anticoagulant therapy such as
thrombolytic therapy, catheter-based interventions, and
surgical embolectomy have been advocated for patients
with massive PE.5–9
Saddle PE is defined as a visible thromboembolus
straddling the bifurcation of the main pulmonary artery
trunk (Fig. 1).10 The diagnosis of saddle PE causes clinical
alarm because it signals an unstable, large clot burden in the
pulmonary artery, and the possibility of sudden hemody-
namic collapse. However, there are relatively sparse data
documenting clinical outcomes of patients with saddle PE
and uncertainties remain regarding optimal management of
these patients. In this study, we sought to determine the
frequency, clinical presentation, and outcome of patients
with saddle PE diagnosed by computed tomographic angio-
graphy (CTA), by far the most common tool used for
diagnosing PE in recent years.11–14angiography (CTA) demon-
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Patients who underwent CTA over a period of 16 months
from 1 September 2002 to 31 December 2003 at Mayo Clinic
Rochester, MN, were identified by a computer-assisted
search of medical records. Of 3792 patients, 148 patients
(3.9%) who did not authorize the use of their medical
records for research were excluded resulting in a cohort of
3644 patients. Of these 3644 patients, 546 (15.0%) had
evidence of acute PE on CTA. The scans of these 546 patients
were reviewed with a particular focus on thromboembolism
located in the central pulmonary vessels. Cases of saddle PE
were identified by the presence of a filling defect extending
across the bifurcation of the main pulmonary artery trunk.10
We examined these cases of saddle PE in detail by extracting
data regarding demographics, clinical presentation, clinical
and radiologic features, as well as treatment and clinical
outcome from the medical records. The 95% confidence
interval for the in-hospital mortality rate was calculated
using a method previously described.15
CTA was performed with a multidetector-row helical CT
scanner using previously described methods.16 The following
CT scanners were used: a 16-slice scanner (Siemens
Sensation 16; Siemens Medical Solutions, Forchheim, Ger-
many), an 8-slice scanner (GE Lightspeed/QXl Ultra; General
Electric, Milwaukee, Wisconsin), and a 4-slice scanner (GE
Lightspeed/QXl Plus; General Electric, Milwaukee, Wiscon-
sin). The findings on CTA were reviewed by one of us (GLA),
an experienced chest radiologist, to confirm the presence of
saddle PE.
Results
Among 546 patients diagnosed to have acute PE by CTA at
our institution over a 16-month period we identified 14
patients with saddle PE (2.6%; 95% CI 1.41%, 4.26%); 10 were
men (71%) (Table 1). The age at diagnosis ranged from 36 to
83 years. The most common symptoms at presentation were
dyspnea (72%) followed by syncope (43%). Hypotension
(systolic blood pressure o90mmHg) was documented in 2
patients (14%) and hypoxemia (PaO2p55mmHg or SaO2
p88%) in 1 patient (7%). None of the patients had pre-
existing cardiopulmonary disease. At the time of the CTA, 9
were inpatients (64%), 2 were outpatients (14%), and 3 were
being evaluated in the emergency department (21%). After
the diagnosis of PE was established, initial management for
all patients occurred in the hospital.
All patients had at least one risk factor for venous
thromboembolism (VTE); 11 patients (79%) had 2 or more
risk factors (Table 1). Obesity (BMI430 kg/M2) was the most
common risk factor (64%). Four patients (29%) were under-
going cancer therapy for metastatic gastrointestinal cancer
(2 patients), metastatic melanoma (1 patient), or advanced
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Table 1 Demographic and clinical features of 14










Chest pain 3 (21)
Nausea 2 (14)
Risk factors for venous thromboembolism—no. (%)
Obesity (BMI 430 kg/M2) 9 (64)
Age 460 years 4 (29)
Malignancy 4 (29)
Cancer therapy 4 (29)
Surgery (within 3 months) 4 (29)
Previous venous thromboembolism 2 (14)
Oral contraceptive or estrogen use 2 (14)
Congenital thrombophilia 2 (14)
BMI ¼ body mass index.
Saddle pulmonary embolism diagnosed by CT angiography: Frequency, clinical features and outcome 1539brain tumor (1 patient). Surgery had been performed within
3 months of the diagnostic CTA in 4 patients and consisted of
hysterectomy (2 patients), repair of torn quadriceps tendon
(1 patient), and open reduction/internal fixation of radial
fracture (1 patient). Five patients underwent testing for
thrombophilia and 3 were diagnosed to have thrombophilic
conditions including heterozygosity for factor V Leiden (2
patients) and abnormal fibrinogen (1 patient).
In addition to the saddle PE in all patients (Fig. 1), CTA
also revealed additional filling defects in the main pulmon-
ary arteries in all patients. Leftward shift of the interven-
tricular septum was present in 11 patients (79%). Pulmonary
arteries were enlarged in 5 patients (36%). Small pleural
effusions were noted in 6 patients (43%) and were bilateral
in 3 patients.
Transthoracic echocardiography was performed in 10
patients (71%) within 48 h of the PE diagnosis and revealed
mild to moderate right ventricular (RV) enlargement in 9
patients (90%), mild to severe RV dysfunction in 8 patients
(80%). Estimated RV systolic pressure was obtainable in 8
patients with a median value of 50mmHg (range,
32–62mmHg).
All 14 patients received heparin and warfarin therapy.
Heparin therapy was initiated with intravenous unfractio-
nated heparin in 13 patients (93%) and low-molecular-
weight heparin in the one remaining patient. Five patients
(36%) received additional therapy; thrombolytic therapy
(alteplase) was administered in 1 patient (7%) and inferior
vena caval filter was deployed in 4 patients (29%).
All 14 patients survived their episode of saddle PE and
were discharged from the hospital. The 95% confidence
interval for the in-hospital mortality rate (given zero eventsin 14 patients) associated with saddle PE is 0–23%. Median
duration of hospitalization was 4 days (range, 1–45 days)
after the diagnosis of PE. Only one patient required
hospitalization stay of410 days; an 83-year-old man whose
hospital course was complicated by gastrointestinal bleed-
ing and respiratory failure requiring mechanical ventilation.
This patient eventually died of unknown cause in a nursing
home 5 months after dismissal from the hospital. One other
patient experienced a complication during the hospital
course and consisted of bleeding from a surgical wound that
was managed by temporary discontinuation of anticoagulant
therapy and inferior vena filter placement.
Follow-up information was available in all 14 patients
with a median follow-up duration of 18 months (range, 1–40
months). Three patients discontinued their warfarin therapy
after 6–12 months of treatment. The remaining 11 patients
continued warfarin therapy indefinitely or up to the time of
their death. Four patients (29%) had died following their
hospitalization after intervals of 1, 5, 6, and 12 months,
respectively. Causes of death were known in 3 patients all of
whom died from progressive malignancy. There were no
recurrences of venous thromboembolism documented during
the follow-up period.
Follow-up CTA had been performed in 5 patients (36%)
after a median interval of 26 months (range, 2–32 months)
and revealed improvement in all patients (Fig. 2(a)–(d)).
Four of these patients had evidence of residual chronic PE;
CTA in one patient appeared normal at 32 months following
saddle PE.
Follow-up transthoracic echocardiography was performed
in 7 patients (50%) during the follow-up period with a
median interval of 12 months (range, 1–32 months) after the
diagnosis of saddle PE. All of these follow-up echocardio-
grams demonstrated normal RV size and function except in
one patient who had borderline RV enlargement and mildly
reduced RV function. RV systolic pressure could be esti-
mated in 6 of these patients and the median value was
36mmHg (range, 23–43mmHg).Discussion
Saddle PE represents a large and unstable clot load. Saddle
PE accounted for 2.6% of 546 consecutive patients diagnosed
to have acute PE by CTA at our institution. This finding is
similar to that of Pruszczyk et al.17 who described 5.2% of
their 289 consecutive patients with acute PE to have a
saddle component. Despite its ominous appearance on
radiologic imaging, however, we did not observe any in-
hospital mortality for our study cohort despite a relatively
conservative treatment regimen for most patients. The
results of our study are in agreement with the findings of
Pruszczyk et al.,17 who described 17 patients with saddle PE
diagnosed by CTA in whom the 2-week mortality rate was
5.8%. These short-term mortality rates for patients with
saddle PE are not any higher than in-hospital mortality rate
for all patients with PE that has ranged from 8% to 10% in
previous reports.18–21
In previous reports, the clinical presentation of saddle PE
has varied considerably from complete absence of symptoms
to sudden death.10,17,22–24 In the current study, clinical
presentation associated with saddle PE was similarly
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Figure 2 Serial CTA studies in a 52–year-old woman with saddle PE. At the time of the initial diagnosis (a) she was treated with
heparin and warfarin. Subsequent studies performed at 4 months (b), 20 months (c), and 32 months (d) after the diagnosis
demonstrated gradual improvement in the obstructing thromboembolus while continuing chronic warfarin therapy. Transthoracic
echocardiography performed 32 months after the diagnosis of PE revealed normal right ventricular size and function; estimated right
ventricular systolic pressure was 26mmHg.
J.H. Ryu et al.1540variable from absence of cardiorespiratory symptoms to that
of syncope and hypotension. Although 6 of our patients (43%)
had experienced syncope prior to the diagnosis of saddle PE,
only 2 patients were documented to be hypotensive. In the
study by Enzwelier et al.,10 6 of 17 patients (35%) with
saddle PE had undergone CT scanning for reasons other than
suspected PE and 3 of these 6 patients were asymptomatic.
Pruszczyk et al.17 found no difference in the initial clinical
and echocardiographic parameters between patients with
saddle and non-saddle PE. Specifically, systolic blood
pressure did not differ between these two groups of
patients. Thus, saddle PE is associated with a wide range
of clinical presentations and hemodynamic instability
appears to be relatively uncommon, at least in PE cases
diagnosed by CTA.
The term ‘‘massive PE’’ has been used with varying
connotations and has accounted for 4.2–10% of patients with
PE.5,7,21,25,26 An earlier use of this term referred to the
presence of ‘‘significant filling defects or obstruction of two
or more lobar arteries’’ identified on standard pulmonaryangiography.27 More recently, authors have used this term
referring to PE associated with a large burden of clots in the
central pulmonary vessels, the presence of systemic arterial
hypotension, clinical signs of cardiogenic shock, or echo-
cardiographic signs of right ventricular dysfunction.5–7,28,29
Our study and previous studies suggest that saddle PE is
uncommonly associated with hypotension or shock. Thus,
whether saddle PE can be classified as a form of ‘‘massive
PE’’ depends on the definition used.
Despite a large burden of thromboembolic material in the
pulmonary vasculature, evidence of gradual resolution was
demonstrated by subsequent echocardiographic and CTA
studies. Our results are consistent with the findings of a
recent systematic review on the resolution of PE suggesting
that more than 50% of patients still have residual PE 6
months after the diagnosis.30 Enzwelier et al.10 described
the short-term evolution of saddle PE in 12 patients in
follow-up CTstudies obtained at a mean interval of 7.5 days.
In 8 patients, the saddle portion of the thromboembolus had
resolved; thinning of the embolus at the bifurcation was
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that saddle PE is a ‘‘transient form’’ of acute PE.10 Long-
term follow-up was not provided.
There are conflicting data regarding the prognostic
significance of the clot burden in the pulmonary vascula-
ture.25,27,31–33 Earlier studies found size of the emboli on
standard pulmonary angiography to not correlate with
mortality.27 However, some recent studies utilizing CTA
suggest that quantification of pulmonary vascular occlusion
caused by thromboembolism can be a predictor of mortal-
ity.25,31 These conflicting results may be explained by
differences in study populations as demographic factors,
comorbidities, and clinical features contribute to clinical
outcome in patients with acute PE.34
To clinicians, the diagnosis of massive PE suggests possible
need for aggressive treatment which may include thrombo-
lytic therapy, surgical pulmonary embolectomy, catheter-
based interventional techniques, and inferior vena caval
filter.5–9,35,36 Although all of our 14 patients survived, it is
likely that some patients with acute saddle PE died suddenly
without a diagnostic evaluation as we had previously
documented in an autopsy study.24 Short-term mortality
associated with acute PE is likely determined by multiple
factors including the physiologic status of the cardiopul-
monary system at the time of the embolization, comorbid
factors, age and overall condition of the patient, as well as
the amount of clot load in the pulmonary vasculature.29,30
The acute clinical consequences of saddle PE may be more
serious in patients with pre-existing cardiopulmonary
compromise or other comorbidities. The limitations in the
current study including the retrospective design, small
number of subjects, and limited follow-up data do not
allow definitive conclusions regarding appropriate manage-
ment of patients with saddle PE. Limited data available
including the results described within suggest that the
mortality rate associated with saddle PE diagnosed by CTA in
patients without pre-existing cardiopulmonary disease may
be similar to that associated with PE overall and may not
necessitate aggressive management measures.References
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